SCHEMBL19781497

SCHEMBL19781497

CCCc1ccncc1NN

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AOC1 P19801 11/20 0.53
AOC3 Q16853 10/20 0.53
CYP2E1 P05181 4/20 0.47
CYP2C8 P10632 4/20 0.47
CYP2D6 P10635 4/20 0.47
CYP2A6 P11509 4/20 0.47
CYP2B6 P20813 4/20 0.47
CYP2C19 P33261 4/20 0.47
CYP2C9 P11712 3/20 0.47
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
KDM6B O15054 2/20 0.38
KDM4C Q9H3R0 2/20 0.38
LOXL2 Q9Y4K0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23408471 0.85 AOC1 (0.45) AOC1AOC3CYP2E1CYP2C8CYP2D6
SCHEMBL16257955 0.83 AOC1 (0.65) AOC1AOC3CYP2E1CYP2C8CYP2D6
SCHEMBL10954433 0.76 CYP2E1 (0.51) AOC1AOC3CYP2E1CYP2C8CYP2D6
SCHEMBL8047522 0.75 AOC1 (0.61) AOC1AOC3CYP2E1CYP2C8CYP2D6
SCHEMBL873728 0.72 CYP2E1 (0.49) AOC1AOC3CYP2E1CYP2C8CYP2D6
SCHEMBL7438728 0.72 ALDH1A1 (0.46) CA12CA1CA2CA9
SCHEMBL8271491 0.72 CYP2E1 (0.49) AOC1AOC3CYP2E1CYP2C8CYP2D6
SCHEMBL7468680 0.72 CYP2E1 (0.49) AOC1AOC3CYP2E1CYP2C8CYP2D6
SCHEMBL1369814 0.71 CYP2E1 (0.47) AOC1AOC3CYP2E1CYP2C8CYP2D6
SCHEMBL13625787 0.71 CYP2E1 (0.47) AOC1AOC3CYP2E1CYP2C8CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572364-B2 Pteridinone compounds and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-02-07 US disclosed
WO-2018013615-A1 C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE SAGE THERAPEUTICS, INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572364-B2 Pteridinone compounds and uses thereof DPYD, PKD1, TYMP AOC1 2771/4885AOC3 4369/4885CYP2E1 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.